 | • レポートコード：MRC2301B164 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、243ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に204.3億ドルであった世界の心不全治療市場規模が、2022年に220.6億ドルになり、2027年には351.0億ドルまで、年平均9.43%で成長すると予測しています。本レポートでは、心不全治療の世界市場について調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、治療別（医療機器、医薬品、手術）分析、種類別（診断、予後）分析、ステージ別（ステージA、ステージB、ステージC、ステージD）分析、エンドユーザー別（クリニック、病院、医療研究組織）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況など、以下の構成でお届けします。なお、本書には、Abbott Laboratories、ABIOMED, Inc.、Amgen Inc.、AstraZeneca PLC、Bayer AG、Beckman Coulter, Inc.、Berlin Heart GmbH、Boston Scientific Corporation、Bristol-Myers Squibb Company、Cardiol Therapeutics Inc.、F. Hoffmann-La Roche Ltd.、GlaxoSmithKline PLC、Impulse Dynamics、Jarvik Heart, Inc.、Johnson & Johnson、LivaNova, PLC、Medtronic PLC、Merck & Co., Inc.、Novartis AG、Orion Corporation、Pfizer, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の心不全治療市場規模：治療別 - 医療機器による治療市場規模 - 医薬品による治療市場規模 - 手術による治療市場規模 ・世界の心不全治療市場規模：種類別 - 診断における市場規模 - 予後における市場規模 ・世界の心不全治療市場規模：ステージ別 - ステージAの市場規模 - ステージBの市場規模 - ステージCの市場規模 - ステージDの市場規模 ・世界の心不全治療市場規模：エンドユーザー別 - クリニックにおける市場規模 - 病院における市場規模 - 医療研究組織における市場規模 ・世界の心不全治療市場規模：地域別 - 南北アメリカの心不全治療市場規模 アメリカの心不全治療市場規模 カナダの心不全治療市場規模 ブラジルの心不全治療市場規模 ... - アジア太平洋の心不全治療市場規模 日本の心不全治療市場規模 中国の心不全治療市場規模 インドの心不全治療市場規模 韓国の心不全治療市場規模 台湾の心不全治療市場規模 ... - ヨーロッパ/中東/アフリカの心不全治療市場規模 イギリスの心不全治療市場規模 ドイツの心不全治療市場規模 インドの心不全治療市場規模 フランスの心不全治療市場規模 ロシアの心不全治療市場規模 ... - その他地域の心不全治療市場規模 ・競争状況 ・企業情報 |
The Global Heart Failure Therapeutics Market size was estimated at USD 20.43 billion in 2021 and expected to reach USD 22.06 billion in 2022, and is projected to grow at a CAGR 9.43% to reach USD 35.10 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Heart Failure Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Treatment, the market was studied across Medical Devices, Medicines, and Surgery. The Medical Devices is further studied across Bi-level positive air pressure device, Biventricular Pacemaker, Continuous Positive Air Pressure Device, Heart Pumps, Implantable Cardioverter-Defibrillators, and Implantable Left Ventricular Assist Device. The Medicines is further studied across Angiotensin II Receptor Blockers, Anticoagulant Medicines, Antiplatelet Medicines, Blood Pressure Maintaining Agents, Diuretics, Nitrates, and Statins. The Surgery is further studied across Cardiac Resynchronization, Coronary Artery Bypass Grafting, Coronary Revascularization, Heart Transplant, and Heart Valve Replacement.
Based on Type, the market was studied across Diagnosis and Prognosis.
Based on Stage, the market was studied across Stage A, Stage B, Stage C, and Stage D.
Based on End User, the market was studied across Clinic, Hospital, and Medical Research Organization.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Heart Failure Therapeutics market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Heart Failure Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Heart Failure Therapeutics Market, including Abbott Laboratories, ABIOMED, Inc., Amgen Inc., AstraZeneca PLC, Bayer AG, Beckman Coulter, Inc., Berlin Heart GmbH, Boston Scientific Corporation, Bristol-Myers Squibb Company, Cardiol Therapeutics Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Impulse Dynamics, Jarvik Heart, Inc., Johnson & Johnson, LivaNova, PLC, Medtronic PLC, Merck & Co., Inc., Novartis AG, Orion Corporation, and Pfizer, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Heart Failure Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Heart Failure Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Heart Failure Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Heart Failure Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Heart Failure Therapeutics Market?
6. What is the market share of the leading vendors in the Global Heart Failure Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Heart Failure Therapeutics Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising Prevalence of Cardiovascular Diseases Among Geriatric Population
5.1.1.2. Growing Susceptibility to Heart Failure and Arrhythmia Owing to Changing Lifestyles
5.1.1.3. Availability and Preferences of Early Diagnosis and Management for Heart Failure
5.1.2. Restraints
5.1.2.1. High Cost and Reimbursement Issues Related to Heart Failure Treatment
5.1.3. Opportunities
5.1.3.1. Innovations and Development in the Heart Failure Therapeutics
5.1.3.2. Ongoing Government Initiatives and Increasing Investments by Private Sectors
5.1.4. Challenges
5.1.4.1. Concerns Related to Management of Heart Failure Condition
5.2. Cumulative Impact of COVID-19
6. Heart Failure Therapeutics Market, by Treatment
6.1. Introduction
6.2. Medical Devices
6.3.1. Bi-level positive air pressure device
6.3.2. Biventricular Pacemaker
6.3.3. Continuous Positive Air Pressure Device
6.3.4. Heart Pumps
6.3.5. Implantable Cardioverter-Defibrillators
6.3.6. Implantable Left Ventricular Assist Device
6.3. Medicines
6.4.1. Angiotensin II Receptor Blockers
6.4.2. Anticoagulant Medicines
6.4.3. Antiplatelet Medicines
6.4.4. Blood Pressure Maintaining Agents
6.4.5. Diuretics
6.4.6. Nitrates
6.4.7. Statins
6.4. Surgery
6.5.1. Cardiac Resynchronization
6.5.2. Coronary Artery Bypass Grafting
6.5.3. Coronary Revascularization
6.5.4. Heart Transplant
6.5.5. Heart Valve Replacement
7. Heart Failure Therapeutics Market, by Type
7.1. Introduction
7.2. Diagnosis
7.3. Prognosis
8. Heart Failure Therapeutics Market, by Stage
8.1. Introduction
8.2. Stage A
8.3. Stage B
8.4. Stage C
8.5. Stage D
9. Heart Failure Therapeutics Market, by End User
9.1. Introduction
9.2. Clinic
9.3. Hospital
9.4. Medical Research Organization
10. Americas Heart Failure Therapeutics Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Heart Failure Therapeutics Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Heart Failure Therapeutics Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. ABIOMED, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Amgen Inc.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. AstraZeneca PLC
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bayer AG
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Beckman Coulter, Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Berlin Heart GmbH
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Boston Scientific Corporation
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Bristol-Myers Squibb Company
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Cardiol Therapeutics Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. F. Hoffmann-La Roche Ltd.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. GlaxoSmithKline PLC
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Impulse Dynamics
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Jarvik Heart, Inc.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Johnson & Johnson
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. LivaNova, PLC
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Medtronic PLC
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Merck & Co., Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Novartis AG
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Orion Corporation
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Pfizer, Inc.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
